The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer

Purpose VEGF is one of the most important angiogenesis-stimulating cytokines and has been previously shown to be overexpressed in several solid cancers. The aim of the present study was to assess the clinical relevance of serum VEGF (sVEGF) in a large cohort of metastatic breast cancer patients and...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2018-11, Vol.172 (1), p.93-104
Main Authors: Banys-Paluchowski, Malgorzata, Witzel, Isabell, Riethdorf, Sabine, Pantel, Klaus, Rack, Brigitte, Janni, Wolfgang, Fasching, Peter A., Aktas, Bahriye, Kasimir-Bauer, Sabine, Hartkopf, Andreas, Solomayer, Erich-Franz, Fehm, Tanja, Müller, Volkmar
Format: Article
Language:English
Subjects:
Angiogenesis
Biological markers
Biomarkers
Biomarkers, Tumor
Breast cancer
Breast Neoplasms - blood
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Cancer metastasis
Cancer research
Care and treatment
Clinical Trial
Clinical trials
Cyclin-dependent kinase inhibitor p21
Cytokines
Enzyme-linked immunosorbent assay
Epidermal growth factor receptors
ErbB-2 protein
Female
Humans
Kaplan-Meier Estimate
Medicine
Medicine & Public Health
Metastases
Metastasis
Multivariate analysis
Neoplasm Metastasis
Neoplasm Staging
Neoplastic Cells, Circulating - pathology
Oncology
Patients
Prognosis
Risk Factors
Tissue inhibitor of metalloproteinase 1
Tumor cells
Vascular endothelial growth factor
Vascular Endothelial Growth Factor A - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose VEGF is one of the most important angiogenesis-stimulating cytokines and has been previously shown to be overexpressed in several solid cancers. The aim of the present study was to assess the clinical relevance of serum VEGF (sVEGF) in a large cohort of metastatic breast cancer patients and to explore the relationship between sVEGF and other blood-based biomarkers. Methods Two hundred fifty-three patients with metastatic breast cancer were enrolled in this prospective, multicentre study. Blood samples were collected before start of first-line or later-line treatment. sVEGF was quantified by a commercially available ELISA. Circulating tumor cells (CTCs) were detected using CellSearch and other biomarkers (EGFR, HER2, RAS p21, TIMP1, CAIX) by ELISA. Results Levels of sVEGF were determined in all patients, with a median concentration of 231 pg/ml. After a median follow-up of 19 months, median overall survival (OS) was 10.2 months in patients with sVEGF levels above the upper quartile (i.e. 367 pg/ml), while median OS has not been reached in patients with sVEGF 
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-018-4882-z